ICU Medical(US:ICUI)2025-02-28 03:562023-2024 Revenue Performance - Total ICU adjusted revenue for 2023 was $2,213 million, while for 2024 it reached $2,335 million[6] - Consumables revenue grew by 7% year-over-year (YoY) in 2024, reaching $1,039 million compared to $969 million in 2023[6] - Infusion Systems revenue increased by 4% YoY in 2024, totaling $652 million versus $629 million in 2023[6] - Vital Care revenue saw a 5% YoY increase in 2024, amounting to $644 million compared to $615 million in 2023[6] 2025 Guidance (Excluding JV Transaction) - Adjusted EBITDA is projected to be between $395 million and $425 million[8] - Adjusted EPS is expected to be in the range of $655 to $725[8] - Revenue growth is anticipated to face a currency headwind of 10 to 15 percentage points[8] - Consumables and Infusion Systems are both expected to experience mid-single-digit growth[8] - Vital Care is projected to remain flat[8] - Gross Margin (GM) % is estimated to be between 37% and 38%[8] - OPEX % is expected to be approximately 24% of revenue[8] - Net interest expense is projected to be around $95 million[8] - The effective tax rate (ETR) is estimated at approximately 25%[8] - Diluted shares are expected to be 247 million[8] - Capital expenditure (CapEx) is projected to be between $90 million and $110 million[8] 2025 Guidance (Post JV Transaction) - Adjusted EBITDA is projected to be between $380 million and $405 million[8] - Adjusted EPS is expected to be in the range of $655 to $725[8] - Vital Care is expected to have flat ~ (37%) organic growth[8] - Gross Margin (GM) % is estimated to be between 39% and 40%[8] - OPEX % is expected to be approximately 26% of revenue[8] - Net interest expense is projected to be around $87 million[8] - Other Income/(Expense) is projected to be around $20 million[8] - The effective tax rate (ETR) is estimated at approximately 25%[8] - Diluted shares are expected to be 247 million[8] - Capital expenditure (CapEx) is projected to be between $75 million and $95 million[8]